MDFirst Research
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pandey, Hemant
TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Recruiting
3
800
Europe, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
06/24
05/25
RETHINK-1, NCT04994483: Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

Active, not recruiting
3
750
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
10/24
10/24
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease

Recruiting
3
600
Japan, US
Remternetug (IV), LY3372993, Remternetug (SC), Placebo
Eli Lilly and Company
Alzheimer's Disease
10/25
10/26
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Active, not recruiting
2
797
Canada, US, RoW
ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline
AEON Biopharma, Inc., PPD
Migraine
06/24
09/24
Guardado, Sean
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Active, not recruiting
2
797
Canada, US, RoW
ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline
AEON Biopharma, Inc., PPD
Migraine
06/24
09/24

Download Options